Skip to content
Peptigraph home
Shop Peptides50% off*

Why am I not losing weight on retatrutide?

The sources cannot diagnose one person's lack of response, but the phase 2 trial shows response varied: at 48 weeks, 10% or more weight loss was reached by 75% of the 4 mg group, 91% of the 8 mg group and 93% of the 12 mg group.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

The sources cannot diagnose one person's lack of response, but the phase 2 trial shows response varied: at 48 weeks, 10% or more weight loss was reached by 75% of the 4 mg group, 91% of the 8 mg group and 93% of the 12 mg group.[1]

What the trials show varies

Weight loss was dose-dependent in the phase 2 trial: 8.7% in the 1 mg group at 48 weeks against 24.2% in the 12 mg group.[1]

People with type 2 diabetes lost -18.8% on 12 mg at week 80, a different trial population and length from the adult trial without diabetes, so the two are not a head-to-head comparison.[2]

In the trial without diabetes, 12 mg gave -25.0% while 4 mg gave -17.6%, so the average gap between dose arms was several percentage points.[3]

Even in a trial, some participants were disappointed: some interviewed trial participants described frustration with disappointing weight loss (n = 3).[4]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

ResultsStudy outcomes and when they were measured.Retatrutide overview

Sources

  1. 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
  2. 2Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  3. 3Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
  4. 4Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.Obesity pillars · 2025PMID 41216380Accessed 2 Oct 2026

Found an error? Report a correction.